Sentences with phrase «haemopoietic cell transplantation»
Previously, Dr. Nikolic was an Assistant Professor in Medicine at Harvard Medical School where he led an advanced immunology laboratory for tolerance induction and stem - cell transplantation at Massachusetts General Hospital / Harvard Medical School.
http://www.editasmedicine.com/
Over the last 15 years, there have been no successful clinical trials in which fetal cell transplantation into patients resulted in patient improvement.
Rocco Bavuso, left, 22, of Bayside, who was diagnosed with aplastic anemia, meets Christian Verholen, 32, his marrow doner, on May 8, 2018, at the annual Celebration of Life Dinner of North Shore University Hospital's Don Monti Bone Marrow and Stem Cell Transplantation Program at Crest Hollow Country Club in Woodbury.
Islet cell transplantation research in the UK The success of a novel islet transplantation procedure, called the «Edmonton protocol» was reported in an article in the New England Journal of Medicine, 27 July 2000.
The article described how a team of researchers, surgeons and radiologists had successfully carried out a number of islet cell transplantations in people with Type 1 diabetes, in Edmonton, Canada..
It is possible that spider silk could also be used in future for other neurological diseases where cell transplantation plays a role.
Lanza, a physician who had spent the past 20 years working in academic research and biotech on organ and cell transplantation, was one of West's first recruits.
An update search enlarged the pool of study data, but did not change the content of the conclusion of the benefit assessment of stem cell transplantation (SCT) for multiple myeloma conducted in 2012.
«Stem cell transplantation for multiple myeloma: New data did not change conclusion.»
Investigations aimed at determining the downstream targets of LIF would help to clarify the functional importance of LIF in muscle regeneration, and further its potential application in cell transplantation therapy.»
«This treatment is a new form of cell transplantation that utilizes the patient's own cells, so it does not require immunosuppressive drugs and, thus, avoids the side effects of those drugs,» says Scott Nyberg, M.D., Ph.D., a liver transplant surgeon at Mayo Clinic.
UTSW co-authors include: Co-lead author Maria Winter, a research associate; Dr. Luisella Spiga, a postdoctoral researcher; visiting fellow Lisa Büttner; graduate students Elizabeth Hughes and Caroline Gillis, all of Microbiology; Dr. Breck Duerkop, Instructor, Immunology; Cassie Behrendt, a research technician, Immunology; Dr. Lora Hooper, Professor and Chair of Immunology with appointments in Microbiology and in the Center for the Genetics of Host Defense, a HHMI Investigator and holder of the Jonathan W. Uhr, M.D. Distinguished Chair in Immunology, and the Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver Diseases.
The JDF Center for Islet Cell Transplantation will fund 32 researchers to focus on four main goals: Reversing the overactive immune response that kills islet cells; finding new sources for islet cell transplants, such as pigs or genetically engineered cells; persuading the body to accept the transplanted cells without immunosuppressive drugs that often trigger worse side effects than the disease; and overcoming the technical difficulties of transplantation.
The researchers have now reported in the journal Nature that the normal process of blood formation differs from what scientists had previously assumed when using data from stem cell transplantations.
«The ability to control autoimmunity by autologous HSCT [hematopoietic stem cell transplantation] has been demonstrated in other treatment - refractory autoimmune conditions, including neurologic diseases.
Cancer patients undergoing stem cell transplantation face two hurdles: the short - term challenge of having enough white blood cells to fight possible infections immediately following the transplant and the long - term challenge of sustaining stem cell function to maintain immunity.
These findings have significant implications for both human stem cell transplantation and for radiation exposure.
Autologous hematopoietic stem cell transplantation (AHSCT) has been investigated as a treatment for aggressive MS, the rationale for which is immune reconstitution.
«To date, there has been no systematic means of assessing the fidelity of cellular engineering — to determine how closely cells made in a petri dish approximate natural tissues in the body,» says George Q. Daley, MD, PhD, Director of the Stem Cell Transplantation Program at Boston Children's and senior investigator on both studies.
«The concept of exosome therapy is interesting because it could potentially shift our strategy from living - cell transplantation to the use of a non-living agent,» he added.
«Stem cells must be carefully preserved to keep them alive and functioning until the time of transplant, and there are some risks involved in cell transplantation.
Cell transplantation as a treatment for diabetes is still essentially experimental, uses cells from cadavers, requires the use of powerful immunosuppressive drugs, and has been available to only a very small number of patients.
Researchers developed a new type of cell transplantation to treat mice mimicking a rare lung disease that one day could be used to treat this and other human lung diseases caused by dysfunctional immune cells.
Journal reference: JAMA, C - Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
«Advances in stem cell transplantation strategies show promise to improve availability, success.»
Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies.
«To have a therapy at our disposal that safely targets just the T cells causing graft - versus - host disease would represent a major step forward in stem cell transplantation.
In the study, analysis of patient samples demonstrated that high LSC17 scores meant poor outcomes with current standard treatment, even for patients who had undergone allogeneic stem cell transplantation.
«Vision restored in rabbits following stem cell transplantation.»
«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»
«Protection for the gut barrier: New approach may prevent graft - versus - host disease: Activating signal paths could protect patients from dangerous immune reactions after stem cell transplantations.»
The technology to grow NK cells from umbilical cord blood was developed by Nina Shah, M.D., assistant professor and Elizabeth J. Shpall, M.D., professor in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.
Imaging techniques are becoming ever more important in the fields of cellular immunotherapy and stem - cell transplantation, the researchers say.
Zhao and his colleagues are also investigating whether a megakaryocyte niche can be used to help expand human hematopoietic stem cells in vitro and stem cell transplantation for patients.
In this way we hope to lay a clinical groundwork for two new techniques: liver cell transplantation and liver gene therapy.»
«But, based on our data, we believe there is a case for early intervention with personalized antiviral treatments following stem cell transplantation in order to suppress hCMV reactivation.»
For this reason, investigators are actively looking for ways to lessen this cell death (e.g., with growth factors) as well as ways to replace the cells that are lost (e.g., with RPE cell transplantation).
Cell transplantation can compensate for missing CONNEXIN and may improve hearing loss by adding properly functioning CONNEXIN proteins.
The fact that Connexin 30 knockout mice had a higher number of grafted cells than normal mice, and that some of the grafted cells expressed CONNEXIN 30 is a very important finding when considering cell transplantation as a treatment for hereditary hearing loss caused by CONNEXIN deficiency.
Pretreating mice with STAR2 protected them from developing GvHD after immune cell transplantation.
As for treatments, the paper states, «Stem cell transplantation may prove to be a viable approach to treat diseases such as suPAR - associated kidney disease.»
The review presents evidence on the participation of stem cells in corneal wound healing and highlights how stem cell transplantation may be used to fine tune wound healing and provide benefits for patients.
Recently, limbal stem cell transplantation was approved in Europe for the treatment of corneal damage.
Given the challenges of beta - cell transplantation, closed - loop technologies are, with continuing innovation potential, destined to provide a viable alternative for existing insulin pump therapy and multiple daily insulin injections.»
Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many patients with bone marrow failure.
The treatment in the current study, called autologous hematopoietic stem cell transplantation (AHSCT), was given to patients with advanced forms of the disease that had failed to respond to other medications.
Pattern of employment and associated factors in long - term lymphoma survivors 10 years after high - dose chemotherapy with autologous stem cell transplantation.
«It blew my mind,» said George Daley, director of the stem - cell transplantation programme at the Boston Children's Hospital in Massachusetts, who chaired the session.
November 30, 2006 Stem cell expert to enhance pediatric hematology / oncology programs at the University of Chicago Medical Center John Cunningham, MD, a leader in treating hemoglobinopathies and genetic blood disorders, has accepted a position with pediatric hematology / oncology and stem cell transplantation at the University of Chicago Medical Center, effective December 1.
Along with the investigational monoclonal antibody, study participants underwent multi-drug chemotherapy, surgery, radiation and autologous hematopoietic stem cell transplantation.